Caspase inhibition via A3 adenosine receptors: A new cardioprotective mechanism against myocardial infarction

Cardiovascular Drugs and Therapy

Volumn 28, Issue 1, 2014, Pages 19-32

  Hussain, Afthab ^a   Gharanei, Ahmed Mayel ^a   Nagra, Aarondeep Singh ^a   Maddock, Helen L ^a  

^a Institute for Clean Growth and Future Mobility   (United Kingdom)

Author keywords

A3 adenosine receptor; Apoptosis; BAD; Caspase; MEK1 2; PI3K; Reperfusion injury

Indexed keywords

ADENOSINE; ADENOSINE A3 RECEPTOR AGONISTS; ANDROSTADIENES; ANIMALS; APOPTOSIS; BUTADIENES; CARDIOTONIC AGENTS; CASPASE 3; DISEASE MODELS, ANIMAL; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NITRILES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A3; SIGNAL TRANSDUCTION;

EID: 84898825468     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6500-y     Document Type: Article

References (53)

1. Van Wylen DG, Schmit TJ, Lasley RD, Gingell RL, Mentzer Jr RM. Cardiac microdialysis in isolated rat hearts: interstitial purine metabolites during ischemia. Am J Physiol. 1992;262(6 Pt 2):H1934-8.
2. Tucker AL, Linden J. Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res. 1993;27:62-7. (Pubitemid 23035667)
3. Ely SW, Mentzer Jr RM, Lasley RD, Lee BK, Berne RM. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg. 1985;90:549-56. (Pubitemid 16238047)
4. Olafsson B, Forman MB, Puett DW, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation. 1987;76:1135-45. (Pubitemid 17157296)
5. Toombs CF,McGee S, JohnstonWE, Vinten-Johansen J. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation. 1992;86:986-94.
6. Lasley RD, Mentzer Jr RM. Protective effects of adenosine in the reversibly injured heart. Ann Thorac Surg. 1995;60:843-6.
7. Ge ZD, van der Hoeven D,Maas JE,Wan TC, Auchampach JA. A(3) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. J Mol Cell Cardiol. 2010;49:280-6.
8. Maddock HL, Mocanu MM, Yellon DM. Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol. 2002;283:H1307-13.
9. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991;84:350-6.
10. Ge ZD, Peart JN, Kreckler LM, et al. Cl-IB-MECA [2-chloro-N6-(3- iodobenzyl)adenosine-5′-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor. J Pharmacol Exp Ther. 2006;319:1200-10.
11. McIntosh VJ, Lasley RD. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther. 2012;17:21-33.
12. Headrick JP, Lasley RD. Adenosine receptors and reperfusion injury of the heart. Handb Exp Pharmacol. 2009;193:189-214.
13. Jordan JE, Thourani VH, Auchampach JA, Robinson JA, Wang NP, Vinten-Johansen J. A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol. 1999;277(5 Pt 2):H1895-905.
14. Maddock HL, Gardner NM, Khandoudi N, Bril A, Broadley KJ. Protection from myocardial stunning by ischaemia and hypoxia with the adenosine A3 receptor agonist. IB-MECA. Eur J Pharmacol. 2003;477:235-45. (Pubitemid 38366396)
15. Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, et al. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3′- aminoadenosine-5′-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther. 2008;324:234-43. (Pubitemid 350294150)
16. Auchampach JA, Ge ZD, Wan TC, Moore J, Gross GJ. A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol Heart Circ Physiol. 2003;285:H607-13. (Pubitemid 36885891)
17. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol. 1996;118:1461-8. (Pubitemid 26248800)
18. Morrison RR, Teng B, Oldenburg PJ, Katwa LC, Schnermann JB, Mustafa SJ. Effects of targeted deletion of A1 adenosine receptors on postischemic cardiac function and expression of adenosine receptor subtypes. Am J Physiol Heart Circ Physiol. 2006;291:H1875-82. (Pubitemid 44497695)
19. Matot I,Weiniger CF, Zeira E, Galun E, Joshi BV, Jacobson KA. A3 adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. Crit Care. 2006;10:R65.
20. Rivo J, Zeira E, Galun E,Matot I. Activation of A3 adenosine receptor provides lung protection against ischemia-reperfusion injury associated with reduction in apoptosis. Am J Transplant. 2004;4:1941-8. (Pubitemid 39611620)
21. Rivo J, Zeira E, Galun E, Matot I. Activation of A3 adenosine receptors attenuates lung injury after in vivo reperfusion. Anesthesiology. 2004;101:1153-9. (Pubitemid 39430795)
22. Von Lubitz DK, Simpson KL, Lin RC. Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke. Ann N Y Acad Sci. 2001;939:85-96. (Pubitemid 32621718)
23. Von Lubitz DK, Lin RC, Boyd M, Bischofberger N, Jacobson KA. Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur J Pharmacol. 1999;367:157-63. (Pubitemid 29106366)
24. Gao Z, Li BS, Day YJ, Linden J. A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol. 2001;59:76-82. (Pubitemid 32043088)
25. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807-69. (Pubitemid 32267078)
26. Hausenloy DJ. Signalling pathways in ischaemic postconditioning. Thromb Haemost. 2009;101:626-34.
27. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res. 2004;63:305-12. (Pubitemid 38900844)
28. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12:217-34. (Pubitemid 350176695)
29. Shiryaev A, Moens U. Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: menage a trois or menage a quatre? Cell Signal. 2010;22:1185-92.
30. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448-60. (Pubitemid 38210151)
31. Germack R, GriffinM, Dickenson JM. Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes. J Mol Cell Cardiol. 2004;37:989-99. (Pubitemid 39446824)
32. Germack R, Dickenson JM. Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol. 2005;39:429-42. (Pubitemid 41133729)
33. Fox R, Aubert M. Flow cytometric detection of activated caspase-3. Methods Mol Biol. 2008;414:47-56.
34. AbbracchioMP, Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Ann N Y Acad Sci. 1999;890:79-92. (Pubitemid 30040367)
35. Abe J, Baines CP, Berk BC. Role of mitogen-activated protein kinases in ischemia and reperfusion injury : the good and the bad. Circ Res. 2000;86:607-9. (Pubitemid 30208424)
36. Yue TL, Wang C, Gu JL, et al. Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res. 2000;86:692-9. (Pubitemid 30208438)
37. Schulte G, Fredholm BB. Signaling pathway from the human adenosine A(3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. Mol Pharmacol. 2002;62:1137-46. (Pubitemid 35222505)
38. Graham S, Combes P, Crumiere M, Klotz KN, Dickenson JM. Regulation of p42/p44 mitogen-activated protein kinase by the human adenosine A3 receptor in transfected CHO cells. Eur J Pharmacol. 2001;420:19-26. (Pubitemid 32539091)
39. Tracey WR, Magee W, Masamune H, Oleynek JJ, Hill RJ. Selective activation of adenosine A3 receptors with N6-(3-chlorobenzyl)-5′-N- methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation. Cardiovasc Res. 1998;40:138-45. (Pubitemid 28435438)
40. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol. 2005;100:397-403. (Pubitemid 41300494)
41. Lim SY, Davidson SM, Paramanathan AJ, Smith CC, Yellon DM, Hausenloy DJ. The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med. 2008;12:1395-403.
42. Park SS, Zhao H, Jang Y, Mueller RA, Xu Z. N6-(3-iodobenzyl)-adenosine- 5′-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3 beta. J Pharmacol Exp Ther. 2006;318:124-31.
43. Jin YC, Kim KJ, Kim YM, et al. Anti-apoptotic effect of magnolol in myocardial ischemia and reperfusion injury requires extracellular signal-regulated kinase1/2 pathways in rat in vivo. Exp Biol Med. 2008;233:1280-8.
44. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288:H971-6. (Pubitemid 40139686)
45. Danial NN. BAD: undertaker by night, candyman by day. Oncogene. 2008;27 Suppl 1:S53-70.
46. Scabini M, Stellari F, Cappella P, Rizzitano S, Texido G, Pesenti E. In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation. Apoptosis. 2011;16:198-207.
47. Schulman D, Latchman DS, Yellon DM. Urocortin protects the heart from reperfusion injury via upregulation of p42/p44MAPK signaling pathway. Am J Physiol Heart Circ Physiol. 2002;283:H1481-8.
48. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA, et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem. 2000;275:8508-14. (Pubitemid 30180198)
49. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001;89:1191-8. (Pubitemid 34627878)
50. Guo WP, Fu XG, Jiang SM, Wu JZ. Neuregulin-1 regulates the expression of Akt, Bcl-2, and Bad signaling after focal cerebral ischemia in rats. Biochem Cell Biol. 2010;88:649-54.
51. Mehrhof FB, Muller FU, Bergmann MW, et al. In cardiomyocyte hypoxia, insulin-like growth factor-I-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation. 2001;104:2088-94. (Pubitemid 33027051)
52. Thourani VH, Nakamura M, Ronson RS, Jordan JE, Zhao ZQ, Levy JH, et al. Adenosine A(3)-receptor stimulation attenuates postischemic dysfunction through K(ATP) channels. Am J Physiol. 1999;277(1 Pt 2):H228-35. (Pubitemid 29354697)
53. Yang XM, Krieg T, Cui L, Downey JM, Cohen MV. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol. 2004;36:411-21. (Pubitemid 38316946)